Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBT (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed EBT for 7 consecutive years, with -$39.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 32.13% to -$39.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$191.1 million through Dec 2025, up 24.53% year-over-year, with the annual reading at -$190.9 million for FY2025, 25.77% up from the prior year.
  • EBT hit -$39.1 million in Q4 2025 for Allogene Therapeutics, up from -$41.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.9 million in Q4 2021 to a low of -$97.0 million in Q1 2023.
  • Historically, EBT has averaged -$63.2 million across 5 years, with a median of -$65.8 million in 2024.
  • Biggest five-year swings in EBT: skyrocketed 102.76% in 2021 and later crashed 5046.54% in 2022.
  • Year by year, EBT stood at $1.9 million in 2021, then plummeted by 5046.54% to -$93.6 million in 2022, then grew by 15.8% to -$78.8 million in 2023, then increased by 27.02% to -$57.5 million in 2024, then skyrocketed by 32.13% to -$39.1 million in 2025.
  • Business Quant data shows EBT for ALLO at -$39.1 million in Q4 2025, -$41.3 million in Q3 2025, and -$50.9 million in Q2 2025.